Abstract: Most of patients with epithelial ovarian cancer was advanced as the initial treatment. Although cytoreductive
surgery and adjuvant paclitaxel/platinum-based chemotherapy have made the most of patients in clinical remission， but there are still 80% of patients to relapse eventually. The principle of treatment for recurrent EOC is palliative rather than cure. The quality of life should be to consider once again on treatment. According to the situation in patients with initial surgery and postoperative chemotherapy and means， efficacy， toxicity， relapse types ，the treatment programs was to be developed individually in order to alleviate and control symptoms of the disease， and improve quality of life and prolong progression-free survival for patient. As only a single lesion or recurrence lesion reduction by surgery effectively，the cytoreductive surgery combined with chemotherapy would be to implement. While those with large and extensive metastasis even， the only chemotherapy would be to consider. In developing the program of chemotherapy， drug-resistant， refractory and refractory patients was often considered as a group， which would be to encourage to ongoing clinical trials or receiving non-platinum chemotherapy， the patients with sensitive ovarian cancer was recommended to receive platinum or platinum plus paclitaxel-based chemotherapy. Biological treatment as an alternative cancer therapy model was more and more attended as an importance strong complement to traditional surgery and chemotherapy.

Key words: Ovarian neoplasms, Carcinoma, Neoplasm recurrence, local, Antineoplastic combined chemotherapyprotocols, Cisplatin